Value of central analysis of leucocyte depletion quality control data within the National Blood Service, England

Background and Objectives The results of quality monitoring leucocyte counts were analysed nationally for the first 2 years of universal leucocyte depletion (LD), spanning the time‐period before and after standardization of the counting and LD methods. The objectives were twofold: first to determine whether the implementation strategy was effective in achieving the LD specification (< 5 × 106 leucocytes in 99% of components with 95% statistical confidence); and second, whether quality monitoring was able to detect potential non‐conformance.

[1]  M. Murphy,et al.  British Committee for Standards in Haematology, Blood Transfusion Task Force (Chairman , 1998 .

[2]  Mccoll,et al.  Quality assurance by a commercial flow cytometry method of leucodepletion of whole blood donations: initial application of universal testing and proposals for a batch‐release sampling plan , 2000, Transfusion medicine.

[3]  F. Claas,et al.  Alloimmunization against the MHC antigens after platelet transfusions is due to contaminating leukocytes in the platelet suspension. , 1981, Experimental hematology.

[4]  E R JENNINGS,et al.  The use of control charts in the clinical laboratory. , 1950, American journal of clinical pathology.

[5]  Amit Mitra,et al.  Statistical Quality Control , 2002, Technometrics.

[6]  Napier.  Guide to the Preparation, Use and Quality Assurance of Blood Components. , 1998 .

[7]  Knowles,et al.  Guidelines on the clinical use of leucocyte‐depleted blood components , 1998, Transfusion medicine.

[8]  J. Reilly,et al.  The development of a national standardized approach for the enumeration of residual leucocytes in blood components , 2002, Vox sanguinis.

[9]  P. Morris,et al.  Alloimmunisation to HLA Antigens following Transfusion with Leucocyte‐Poor and Purified Platelet Suspensions , 1985, Vox sanguinis.

[10]  R. F.,et al.  Statistical Method from the Viewpoint of Quality Control , 1940, Nature.

[11]  P. Rebulla,et al.  Practical guidelines for process validation and process control of white cell‐reduced blood components: report of the Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT) , 1996, Transfusion.